Insight Molecular Diagnostics (7OC0) Q2 2026 Earnings Report

The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.

The company guided that it still targets FDA marketing authorization “later this year” (subject to agency timing) and will hold an SIR meeting before submitting additional data—since March it has roughly tripled study sample collection; Q2 adjusted EBITDA loss narrowed to $7.8M and cash burn was $10M (the expected high watermark), with an updated cash‑burn outlook of ≈$8M/quarter in H2 (versus a prior ≈$6M/quarter); management expects modest H2 revenue from laboratory services, RUO kit sales (≈$21k in Q2) and GraftAssureCore (reimbursable at $2,753/result), is fully staffed for material revenue growth, sees >50% of top‑10 U.S. transplant centers engaged and ~50% overlap of FDA sites into the registry, models a $2B core TAM based on 2 tests/year (and notes MolDX expanded surveillance from 8→14 tests in the first 3 years post‑kidney transplant will grow TAM), believes it is ~2 years ahead on kitted development versus competitors, and continues to target IVDR/UK self‑certification and commercial readiness in H2.